GW&K Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $84.5M | Sell |
350,667
-20,431
| -6% | -$4.48M | 0.66% | 36 |
|
|
2026
Q1 | $70.2M | Sell |
371,098
-56,546
| -13% | -$9.88M | 0.62% | 38 |
|
|
2025
Q4 | $72.7M | Sell |
427,644
-27,068
| -6% | -$4.15M | 0.63% | 34 |
|
|
2025
Q3 | $59.9M | Sell |
454,712
-17,849
| -4% | -$2.14M | 0.53% | 57 |
|
|
2025
Q2 | $50.1M | Buy |
472,561
+2,015
| +0.4% | +$219K | 0.45% | 75 |
|
|
2025
Q1 | $58.4M | Buy |
470,546
+6,543
| +1% | +$854K | 0.54% | 52 |
|
|
2024
Q4 | $57.1M | Buy |
464,003
+97,589
| +27% | +$11.5M | 0.49% | 67 |
|
|
2024
Q3 | $40.8M | Sell |
366,414
-2,932
| -0.8% | -$321K | 0.35% | 113 |
|
|
2024
Q2 | $39.4M | Buy |
369,346
+5,600
| +2% | +$616K | 0.36% | 108 |
|
|
2024
Q1 | $43.8M | Sell |
363,746
-3,119
| -0.9% | -$382K | 0.39% | 108 |
|
|
2023
Q4 | $45.1M | Sell |
366,865
-19,980
| -5% | -$2.49M | 0.42% | 90 |
|
|
2023
Q3 | $50.1M | Sell |
386,845
-15,479
| -4% | -$2.06M | 0.5% | 74 |
|
|
2023
Q2 | $49.9M | Sell |
402,324
-9,802
| -2% | -$1.32M | 0.47% | 81 |
|
|
2023
Q1 | $60.3M | Buy |
412,126
+71,214
| +21% | +$10.5M | 0.58% | 54 |
|
|
2022
Q4 | $54.3M | Sell |
340,912
-9,019
| -3% | -$1.32M | 0.55% | 61 |
|
|
2022
Q3 | $46.6M | Sell |
349,931
-27,106
| -7% | -$4.12M | 0.51% | 68 |
|
|
2022
Q2 | $58.8M | Sell |
377,037
-42,705
| -10% | -$6.57M | 0.63% | 40 |
|
|
2022
Q1 | $65.3M | Buy |
419,742
+19,649
| +5% | +$2.85M | 0.58% | 48 |
|
|
2021
Q4 | $51M | Buy |
400,093
+134,029
| +50% | +$17.6M | 0.43% | 95 |
|
|
2021
Q3 | $34.6M | Sell |
266,064
-3,345
| -1% | -$505K | 0.31% | 144 |
|
|
2021
Q2 | $47.9M | Buy |
269,409
+3,962
| +1% | +$686K | 0.42% | 97 |
|
|
2021
Q1 | $43.6M | Buy |
265,447
+29,558
| +13% | +$4.86M | 0.4% | 103 |
|
|
2020
Q4 | $38.9M | Buy |
235,889
+14
| +0% | +$2.08K | 0.41% | 98 |
|
|
2020
Q3 | $33.6M | Buy |
235,875
+42,982
| +22% | +$5.33M | 0.44% | 90 |
|
|
2020
Q2 | $21.3M | Buy |
192,893
+1,375
| +0.7% | +$152K | 0.3% | 149 |
|
|
2020
Q1 | $19.1M | Buy |
191,518
+9,618
| +5% | +$1.24M | 0.34% | 124 |
|
|
2019
Q4 | $27.2M | Sell |
181,900
-5,788
| -3% | -$788K | 0.36% | 123 |
|
|
2019
Q3 | $24.1M | Buy |
187,688
+53,512
| +40% | +$7.17M | 0.34% | 134 |
|
|
2019
Q2 | $19.1M | Buy |
134,176
+1,188
| +0.9% | +$160K | 0.29% | 156 |
|
|
2019
Q1 | $19M | Buy |
132,988
+46,583
| +54% | +$6.08M | 0.31% | 150 |
|
|
2018
Q4 | $10.7M | Buy |
+86,405
| New | +$12.8M | 0.21% | 172 |
|
Other funds holding JAZZ
GW&K Investment Management's JAZZ Position: Q2 2026 in Review
GW&K Investment Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 5.5% in Q2 2026, selling an estimated $4.48M and leaving 350,667 shares worth $84.5M. The position accounts for 0.66% of the portfolio, ranked #36.
GW&K Investment Management first reported a position in JAZZ in Q4 2018 and has held it in 31 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- GW&K Investment Management held 350,667 shares of Jazz Pharmaceuticals worth $84.5M as of Q2 2026.
- GW&K Investment Management sold 20,431 Jazz Pharmaceuticals shares in Q2 2026, an estimated $4.48M.
- Jazz Pharmaceuticals made up 0.66% of GW&K Investment Management's portfolio in Q2 2026, its #36 holding.
- GW&K Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
- 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.